RegenLab, a pioneering biotechnology company specializing in the research, development, and manufacturing of patented cell and tissue engineering medical devices, has been honored with the “Innovation Champion Award” by the European Investment Bank (EIB) at the European Convention Center in Luxembourg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611846846/en/
RegenLab France receives prestigious EU-EIB Innovation Champion Award. Antoine Turzi, CEO and Founder of RegenLab, pictured between two officials of the European Investment Bank. (Photo: Business Wire)
This prestigious award recognizes RegenLab France’s commitment to “reshoring” by establishing a state-of-the-art biotechnology factory in Paris-Saclay and its innovation, the REGENMATRIX® PRP-HA. This next-generation product combines Platelet-Rich Plasma (PRP) with cross-linked Hyaluronic Acid (HA) in a single tube, designed specifically to address the needs of patients with advanced grade III-IV knee osteoarthritis. Currently, a clinical study is underway in 16 university hospitals across France to demonstrate the effectiveness and safety of this groundbreaking treatment.
“We are honored and delighted to receive this award from the European Investment Bank,” said Mr. Antoine Turzi, Founder & CEO of RegenLab France. “This recognition celebrates the successful completion of our French factory and our ongoing R&D efforts. Our goal is to innovate in cell therapies and enhance the well-being of patients, while supporting industry reshoring in France.”
RegenLab’s achievement not only highlights its dedication to advancing medical science but also underscores the pivotal role of the EIB in promoting innovation, its sustainable growth across Europe and its competitiveness worldwide.
Based in Paris Saclay, RegenLab France is a company specialized in the R&D and manufacturing of tissue engineering medical devices supported by 100 patents. The Company’s solutions are commercialized in more than 90 countries. The core technology of the Company is manufacturing of medical devices for autologous platelet-rich plasma (PRP) & Tissue Engineering, consisting in reinjecting the patient’s own cells and platelets into tissue lesions in order to stimulate tissue healing. The RegenKit, CellularMatrix… brands, have been CE marked EU-MDR 2017/745 and approved by US-FDA, CFDA & worldwide regulatory agencies; they are routinely used for the treatment of a wide variety of indications including joint osteoarthritis, tendinopathies, woman health and dermo-aesthetics. The Company’s medical devices are also manufactured in the factory of Le Mont-sur-Lausanne (Switzerland) & New York (USA).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611846846/en/
Contact details:
RegenLab France SAS | +33 1 77 44 60 60 | [email protected]
Antoine Turzi | C.E.O.
Hubert de Pombriant I General Manager
Jean-Marc Biscarrat | Chief Financial Officer
